For those in the stock market, here is more info on Enzolytics (ENZC)... If you're in the market, you know how to do your DD on companies, but everything seems to be lining up for them. The stock is still barely 4 cents, so it's ground floor. It's potentially life changing, and that's why I post it. if the stock were $150, I wouldn't.
I might in the future say "Hey, remember that stock that was 4 cents and is now $150"???
Enzolytics is under multiple non disclosure agreements (NDA's), and speculation is that one is for a Covid Monoclonal Antibody they developed and are in partnership with Regeneron to produce it.
They are already in business with Samsung Bio to produce their HIV Monoclonal Antibody.
From Enzolytics' website. This discusses the ability of their AI to identify the target areas of viruses.
"Application of computer analysis (Artificial Intelligence – A.I.) to curate (analyze) the amino acid sequences of targeted viruses to identify the conserved, immutable, and neutralizable target sites (epitopes) on targeted viruses. Enzolytics has accomplished this goal for HIV, the Coronavirus, HTLV-1, as well as for H10N3, Influenza A, and B, H1N1 influenza, Respiratory syncytial virus (RSV), Ebola, Small-Pox, Tetanus, Diphtheria, Rabies, Herpes zoster, Varicella zoster, Anthrax, Elephant endotheliotropic herpesviruses, Feline Leukemia Virus, Equine Infectious Anemia Virus, Feline Immunodeficiency virus, Small Ruminant Lentivirus, and Koala retrovirus."
"
Regeneron, which early on in the pandemic developed a monoclonal antibody cocktail to address a treatment paradigm for COVID, is pivoting to what CEO
Len Schleifer called “the jackpot antibody.”
In response to the original antibodies losing their efficacy, the company has developed a new one. The drug, dubbed
REGN-14287, “has demonstrated potency against all known SARS variants and lineages to date,” reported Regeneron chief scientific officer
George Yancopoulos, adding that the biotech expects the drug to enter clinical development later this year."
https://www.mmm-online.com/home/channel/jpm23-week-storm-prep-top-of-mind-for-biopharma-ceos/
Slide 27 shows the efficacy of 14287... Every other MAB is claimed by the company that founded it. If they are under NDA's with Enzolytics, they can't say anything about that until both companies agree to terminate the NDA.
https://investor.regeneron.com/static-files/5f682777-4984-400b-bacb-3041044bb4b6
1:47 in the video...